AstraZeneca PLC (NASDAQ:AZN – Get Free Report) declared a Semi-Annual dividend on Thursday, July 25th, Zacks reports. Shareholders of record on Friday, August 9th will be paid a dividend of 0.49 per share on Monday, September 9th. The ex-dividend date is Friday, August 9th.
AstraZeneca has raised its dividend payment by an average of 1.2% annually over the last three years. AstraZeneca has a payout ratio of 41.7% meaning its dividend is sufficiently covered by earnings. Equities analysts expect AstraZeneca to earn $4.68 per share next year, which means the company should continue to be able to cover its $1.97 annual dividend with an expected future payout ratio of 42.1%.
AstraZeneca Stock Performance
Shares of AZN stock opened at $78.13 on Friday. The company’s fifty day simple moving average is $78.54 and its 200-day simple moving average is $71.92. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73. The firm has a market cap of $242.25 billion, a PE ratio of 38.30, a P/E/G ratio of 1.42 and a beta of 0.45. AstraZeneca has a 12 month low of $60.47 and a 12 month high of $80.86.
Analysts Set New Price Targets
A number of analysts have recently commented on AZN shares. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Barclays upgraded shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. The Goldman Sachs Group began coverage on shares of AstraZeneca in a report on Thursday, May 30th. They set a “buy” rating and a $97.00 target price on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. Finally, BMO Capital Markets boosted their target price on shares of AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, April 26th. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $88.00.
Check Out Our Latest Report on AZN
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
- Five stocks we like better than AstraZeneca
- 3 Healthcare Dividend Stocks to Buy
- Why Call Options Volume for These 2 Stocks Spiked Together
- Stock Sentiment Analysis: How it Works
- MarketBeat Week in Review – 7/22 – 7/26
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.